Molecules that target key events in macrophage migration during inflammation

Bibliography

• GENG JG: Directional migration of leukocytes: their pathological roles in inflammation and strategies for development of anti-inflammatory therapies. Cell Res. (2001) 11(2):85–88.
   PubMedGoogle Scholar
• •A good summary of the migration of leukocytes.
   Google Scholar
• MORRISSETTE N, GOLD E, ADEREM A: The macrophage: a cell for all seasons. Trends Cell Biol. (1999) 9(5):199–201.
   PubMedGoogle Scholar
• MULLER WA: Migration of leukocytes across endothelial junctions: some concepts and controversies. Microcircifiation (2001) 8(3):181–193.
   PubMed Web of Science ®Google Scholar
• RADI ZA, KEHRLI ME Jr, ACKERMANN MR: Cell adhesion molecules, leukocyte trafficking, and strategies to reduce leukocyte infiltration. Vet. Intern. Med. (2001) 15(6):516–529.
   PubMed Web of Science ®Google Scholar
• HARLAN JM, WINN RK: Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit. Care Med. (2002) 30(Suppl.):214–219.
   Google Scholar
• NORMAN KE, SCHEDING C, KUNKEL EJ, HEAVNER GA, LEY K: Peptides derived from the lectin domain of selectin adhesion molecules inhibit leukocyte rolling in vivo. Microcirculation (1996) 3(1):29–38.
   PubMedGoogle Scholar
• TEDDER TF, STEEBER DA, PIZCUETA P: L-selectin-deficient mice have impaired leukocyte recruitment into inflammatory sites. I Exp. Med. (1995) 181(6):2259–2264.
   PubMedGoogle Scholar
• TANG ML, HALE LP, STEEBER DA, TEDDER TF: L-selectin is involved in lymphocyte migration to sites of inflammation in the skin: delayed rejection of allografts in L-selectin-deficient mice. Immunol. (1997) 158(11) :5191–5199.
   Google Scholar
• RAINER TH: L-selectin in health and disease. Resuscitation (2002) 52(2):127–141.
   PubMed Web of Science ®Google Scholar
• •An informative overview of this adhesion molecule with details of the potential of L-selectin blockers in the management of inflammation.
   Google Scholar
• SCHON MP, KRAHN T, SCHON M et al.: Efomycine M: a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat. Med. (2002) 8(4):366–672.
   PubMedGoogle Scholar
• O'CONNELL D, KOENIG A, JENNINGS S: Calcium-dependent oligonucleotide antagonists specific for L-selectin. Proc. Nati Acad. Sci.USA (1996) 93(12):5883–5887.
   PubMedGoogle Scholar
• MARTIN KH, SLACK JK, BOERNER SA, MARTIN CC, PARSONS JT: Integrin connections map: to infinity and beyond. Science (2002) 296(5573):1652–1653.
   PubMedGoogle Scholar
• WEERASINGHE D, MCHUGH KP, ROSS FP, BROWN EJ, GISLER RH, IMHOF BA: A role for the a133integrin in the transmigration of monocytes.j. Cell Biol. (1998) 142(2):595–607.
   Google Scholar
• BRINCKERHOFF CE, MATRISIAN LM: Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Ma Cell Biol. (2002) 3(3):207–214.
   PubMed Web of Science ®Google Scholar
• LEPPERT D, LINDBERG RL, KAPPOS L, LEIB SL: Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res. Rev (2001) 36(2-3):249–257.
   PubMedGoogle Scholar
• WHITTAKER M, FLOYD C, BROWN P, GEARING A: Design and therapeutic application of matrix metalloproteinase inhibitors. Chemical Rev. (1999) 99:2735–2776.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ EJ, LOLIS E: Structure, function, and inhibition of chemokines. Ann. Rev Pharmacol Toxicol (2002) 42:469–499.
   PubMed Web of Science ®Google Scholar
• GANGUR V, BIRMINGHAM NP, THANESVORAKUL S: Chemokines in health and disease. Vet. Immunol Immunopathol. (2002) 86(3-4):127–136.
   PubMedGoogle Scholar
• ROSSI D, ZLOTNIK A: The biology of chemokines and their receptors. Ann. Rev Immunol (2000) 18:217–242.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of chemokines and theirreceptors with an informative account of these molecules as targets of immune modulation.
   Google Scholar
• VAN COILLIE E, VAN DAMME J, OPDENAKKER G: The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev (1999) 10(1):61–86.
   PubMed Web of Science ®Google Scholar
• GU L, TSENG SC, ROLLINS BJ: Monocyte chemoattractant protein-1. Chem. Immunol (1999) 72:7–29.
   PubMedGoogle Scholar
• ROLLINS B: Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Ma Med. Today(1996) 2(5):198–204.
   PubMedGoogle Scholar
• JANATPOUR MJ, HUDAK S, SATHE M, SEDGWICK JD, MCEVOY LM: Tumor necrosis factor-dependent segmental control of MIG expression by high endothelial venules in inflamed lymph nodes regulates monocyte recruitment. I Exp. Med. (2001) 194(9):1375–1384.
   PubMedGoogle Scholar
• SCHMITZ G, HERR AS, ROTHE G: T-lymphocytes and monocytes in atherogenesis. Herz (1998) 23(3):168–177.
   PubMedGoogle Scholar
• REAPE TJ, GROOT PH: Chemoldnes and atherosclerosis. Atherosclerosis (1999) 147(2):213–225.
   PubMedGoogle Scholar
• KRAEMER R: Regulation of cell migrationin atherosclerosis. Carr: Atherosclec Rep. (2000) 2(5):445–452.
   PubMedGoogle Scholar
• SCHOLS D, STRUYF S, VAN DAMME J, ESTE JA, HENSON G, DE CLERCQ E: Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. I Exp. Med. (1997) 186(8):1383–1388.
   PubMed Web of Science ®Google Scholar
• MURAKAMI T, NAKAJIMA T, KOYANAGI Y et al.: A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. I Exp. Med. (1997) 186(8):1389–1393.
   PubMed Web of Science ®Google Scholar
• SALLUSTO F, MACKAY CR, LANZAVECCHIA A: The role of chemokine receptors in primary, effector, and memory immune responses. Anna. Rev Immunol (2000) 18:593–620.
   PubMed Web of Science ®Google Scholar
• DORANZ BJ, GROVIT-FERBAS K, SHARRON MP et al.: A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. I Exp. Med. (1997) 186(8):1395–1400.
   PubMed Web of Science ®Google Scholar
• GONG JH, UGUCCIONI M, DEWALD B, BAGGIOLINI M, CLARK-LEWIS I: RANTES and MCP-3 antagonists bind multiple chemokine receptors. Biol. Chem. (1996) 271(18):10521–10527.
   Google Scholar
• ELSNER J, PETERING H, HOCHSTETTER R et al.: The CC chemokine antagonist Met-RANTES inhibits eosinophil effector functions through the chemokine receptors CCR1 and CCR3. Eur.j Immunol (1997) 27(11):2892–2898.
   PubMedGoogle Scholar
• MOSER B, DEWALD B, BARELLA L, SCHUMACHER C, BAGGIOLINI M, CLARK-LEWIS I: Interleuldn-8 antagonists generated by N-terminal modification. I Biol. Chem. (1993) 268(10):7125–7128.
   Google Scholar
• GONG JH, RATKAY LG, WATERFIELD JD, CLARK-LEWIS I: An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. I Exp. Med. (1997) 186(1):131–137.
   PubMedGoogle Scholar
• •Good in vivo study of a chemokine antagonist in a mouse model.
   Google Scholar
• PLATER-ZYBERK C, HOOGEWERF AJ, PROUDFOOT AE, POWER CA, WELLS TN: Effect of a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice. brananol. Lett. (1997) 57(1-3):117–120.
   Google Scholar
• BECK CG, STUDER C, ZUBER JF, DEMANGE BJ, MANNING U, URFER R: The viral CC chemokine-binding protein vCCI inhibits monocyte chemoattractant protein-1 activity by masking its CCR2B-binding site. j Biol. Chem. (2001) 276(46):43270–43276.
   PubMedGoogle Scholar
• •Good research article describing the site on MCP-1 for the viral chemokine binding protein.
   Google Scholar
• DAMON I, MURPHY PM, MOSS B: Broad spectrum chemokine antagonistic activity of a human poxvirus chemokine homolog. Proc. Nati Acad. Sci. USA (1998) 95 (11):6403–6407.
   PubMedGoogle Scholar
• ALCAMI A, SYMONS JA, COLLINS PD, WILLIAMS TJ, SMITH GL: Blockade of chemokine activity by a soluble chemokine binding protein from vaccinia virus. j. Immune]. (1998) 160(2):624–633.
   PubMed Web of Science ®Google Scholar
• RHODES A, SMITHERS N, CHAPMAN T, PARSONS S, REES S: The generation and characterisation of antagonist RNA aptamers to MCP-1. FEBS Lett. (2001) 506(2):85–90.
   PubMedGoogle Scholar